#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	coref	4-1[6_0]
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Human
3-1	17-22	Human	person	new	_	_

#Text=T-lymphotropic virus 1 ( HTLV-1 ) is a Deltaretrovirus , endemic in Japan , Caribbean , South America , Sub-Saharan Africa , and Melanesia .
4-1	23-37	T-lymphotropic	abstract|abstract[5]|abstract[6]	new|new[5]|giv[6]	coref|coref|coref	4-8[8_6]|4-8[8_6]|4-8[8_6]
4-2	38-43	virus	abstract[5]|abstract[6]	new[5]|giv[6]	_	_
4-3	44-45	1	abstract[6]	giv[6]	_	_
4-4	46-47	(	_	_	_	_
4-5	48-54	HTLV-1	abstract	new	coref	5-1
4-6	55-56	)	_	_	_	_
4-7	57-59	is	_	_	_	_
4-8	60-61	a	abstract[8]	giv[8]	_	_
4-9	62-77	Deltaretrovirus	abstract[8]	giv[8]	_	_
4-10	78-79	,	_	_	_	_
4-11	80-87	endemic	_	_	_	_
4-12	88-90	in	_	_	_	_
4-13	91-96	Japan	place	new	_	_
4-14	97-98	,	_	_	_	_
4-15	99-108	Caribbean	place	new	_	_
4-16	109-110	,	_	_	_	_
4-17	111-116	South	place[11]	new[11]	_	_
4-18	117-124	America	place[11]	new[11]	_	_
4-19	125-126	,	_	_	_	_
4-20	127-138	Sub-Saharan	place[12]	new[12]	_	_
4-21	139-145	Africa	place[12]	new[12]	_	_
4-22	146-147	,	_	_	_	_
4-23	148-151	and	_	_	_	_
4-24	152-161	Melanesia	place	new	_	_
4-25	162-163	.	_	_	_	_

#Text=HTLV-1 is associated with several different types of diseases .
5-1	164-170	HTLV-1	abstract	giv	coref	8-34
5-2	171-173	is	_	_	_	_
5-3	174-184	associated	_	_	_	_
5-4	185-189	with	_	_	_	_
5-5	190-197	several	abstract[15]	new[15]	_	_
5-6	198-207	different	abstract[15]	new[15]	_	_
5-7	208-213	types	abstract[15]	new[15]	_	_
5-8	214-216	of	abstract[15]	new[15]	_	_
5-9	217-225	diseases	abstract[15]|abstract	new[15]|new	coref	7-24[30_0]
5-10	226-227	.	_	_	_	_

#Text=Adult T-cell leukemia/lymphoma ( ATLL ) develops in up to 5 % of infected people , and sometimes a chronic neurodegenerative inflammatory disease called HTLV-1-associated myelopathy ( HAM ) develops .
6-1	228-233	Adult	abstract[17]	new[17]	appos	6-5[0_17]
6-2	234-240	T-cell	abstract[17]	new[17]	_	_
6-3	241-258	leukemia/lymphoma	_	_	_	_
6-4	259-260	(	_	_	_	_
6-5	261-265	ATLL	abstract	giv	coref	19-15[134_0]
6-6	266-267	)	_	_	_	_
6-7	268-276	develops	_	_	_	_
6-8	277-279	in	_	_	_	_
6-9	280-282	up	_	_	_	_
6-10	283-285	to	_	_	_	_
6-11	286-287	5	quantity[19]	new[19]	_	_
6-12	288-289	%	quantity[19]	new[19]	_	_
6-13	290-292	of	quantity[19]	new[19]	_	_
6-14	293-301	infected	quantity[19]|person[20]	new[19]|new[20]	coref	7-2[24_20]
6-15	302-308	people	quantity[19]|person[20]	new[19]|new[20]	_	_
6-16	309-310	,	_	_	_	_
6-17	311-314	and	_	_	_	_
6-18	315-324	sometimes	abstract[21]	new[21]	coref	9-17[47_21]
6-19	325-326	a	abstract[21]	new[21]	_	_
6-20	327-334	chronic	abstract[21]	new[21]	_	_
6-21	335-352	neurodegenerative	abstract[21]	new[21]	_	_
6-22	353-365	inflammatory	abstract[21]	new[21]	_	_
6-23	366-373	disease	abstract[21]	new[21]	_	_
6-24	374-380	called	_	_	_	_
6-25	381-398	HTLV-1-associated	abstract[22]	new[22]	_	_
6-26	399-409	myelopathy	abstract[22]	new[22]	_	_
6-27	410-411	(	_	_	_	_
6-28	412-415	HAM	substance	new	coref	10-1
6-29	416-417	)	_	_	_	_
6-30	418-426	develops	_	_	_	_
6-31	427-428	.	_	_	_	_

#Text=Although a high percentage of people remain asymptomatic during their lifetime , a great number of infected people develop a large range of neurological diseases .
7-1	429-437	Although	_	_	_	_
7-2	438-439	a	person[24]	giv[24]	coref	7-17[28_24]
7-3	440-444	high	person[24]	giv[24]	_	_
7-4	445-455	percentage	person[24]	giv[24]	_	_
7-5	456-458	of	person[24]	giv[24]	_	_
7-6	459-465	people	person[24]	giv[24]	_	_
7-7	466-472	remain	_	_	_	_
7-8	473-485	asymptomatic	_	_	_	_
7-9	486-492	during	_	_	_	_
7-10	493-498	their	person|time[26]	acc|new[26]	_	_
7-11	499-507	lifetime	time[26]	new[26]	_	_
7-12	508-509	,	_	_	_	_
7-13	510-511	a	quantity[27]	new[27]	_	_
7-14	512-517	great	quantity[27]	new[27]	_	_
7-15	518-524	number	quantity[27]	new[27]	_	_
7-16	525-527	of	quantity[27]	new[27]	_	_
7-17	528-536	infected	quantity[27]|person[28]	new[27]|giv[28]	coref	20-6[140_28]
7-18	537-543	people	quantity[27]|person[28]	new[27]|giv[28]	_	_
7-19	544-551	develop	_	_	_	_
7-20	552-553	a	abstract[29]	new[29]	_	_
7-21	554-559	large	abstract[29]	new[29]	_	_
7-22	560-565	range	abstract[29]	new[29]	_	_
7-23	566-568	of	abstract[29]	new[29]	_	_
7-24	569-581	neurological	abstract[29]|abstract[30]	new[29]|giv[30]	coref	9-17[48_30]
7-25	582-590	diseases	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
7-26	591-592	.	_	_	_	_

#Text=Other opportunistic-like infections , such as Strongyloidiasis , Norwegian scabies , infective dermatitis , as well as autoimmune syndromes , including rheumatoid arthritis and Sjögren ’s syndrome , have also been described among HTLV-1 carriers .
8-1	593-598	Other	abstract[31]	new[31]	_	_
8-2	599-617	opportunistic-like	abstract[31]	new[31]	_	_
8-3	618-628	infections	abstract[31]	new[31]	_	_
8-4	629-630	,	abstract[31]	new[31]	_	_
8-5	631-635	such	abstract[31]	new[31]	_	_
8-6	636-638	as	abstract[31]	new[31]	_	_
8-7	639-655	Strongyloidiasis	abstract[31]|substance	new[31]|new	_	_
8-8	656-657	,	abstract[31]	new[31]	_	_
8-9	658-667	Norwegian	abstract[31]|object[33]	new[31]|new[33]	_	_
8-10	668-675	scabies	abstract[31]|object[33]	new[31]|new[33]	_	_
8-11	676-677	,	abstract[31]	new[31]	_	_
8-12	678-687	infective	abstract[31]|abstract[34]	new[31]|new[34]	_	_
8-13	688-698	dermatitis	abstract[31]|abstract[34]	new[31]|new[34]	_	_
8-14	699-700	,	abstract[31]	new[31]	_	_
8-15	701-703	as	abstract[31]	new[31]	_	_
8-16	704-708	well	abstract[31]	new[31]	_	_
8-17	709-711	as	abstract[31]	new[31]	_	_
8-18	712-722	autoimmune	abstract[31]|abstract|abstract[36]	new[31]|new|new[36]	_	_
8-19	723-732	syndromes	abstract[31]|abstract[36]	new[31]|new[36]	_	_
8-20	733-734	,	abstract[31]|abstract[36]	new[31]|new[36]	_	_
8-21	735-744	including	abstract[31]|abstract[36]	new[31]|new[36]	_	_
8-22	745-755	rheumatoid	abstract[31]|abstract[36]|object|abstract[38]	new[31]|new[36]|new|new[38]	_	_
8-23	756-765	arthritis	abstract[31]|abstract[36]|abstract[38]	new[31]|new[36]|new[38]	_	_
8-24	766-769	and	abstract[31]|abstract[36]	new[31]|new[36]	_	_
8-25	770-777	Sjögren	abstract[31]|abstract[36]|person[39]|abstract[40]	new[31]|new[36]|new[39]|new[40]	coref|coref	10-23[63_40]|10-23[63_40]
8-26	778-780	’s	abstract[31]|abstract[36]|person[39]|abstract[40]	new[31]|new[36]|new[39]|new[40]	_	_
8-27	781-789	syndrome	abstract[31]|abstract[36]|abstract[40]	new[31]|new[36]|new[40]	_	_
8-28	790-791	,	_	_	_	_
8-29	792-796	have	_	_	_	_
8-30	797-801	also	_	_	_	_
8-31	802-806	been	_	_	_	_
8-32	807-816	described	_	_	_	_
8-33	817-822	among	_	_	_	_
8-34	823-829	HTLV-1	event|organization[42]	giv|new[42]	coref|coref	18-1|18-1
8-35	830-838	carriers	organization[42]	new[42]	_	_
8-36	839-840	.	_	_	_	_

#Text=In these patients , the clinical conditions appear to be the result of the interaction between the virus and the host susceptibility , leading to the abnormal functioning of immuno-modulatory mechanisms , cell proliferation , and inflammation .
9-1	841-843	In	_	_	_	_
9-2	844-849	these	person[43]	new[43]	coref	15-61[109_43]
9-3	850-858	patients	person[43]	new[43]	_	_
9-4	859-860	,	_	_	_	_
9-5	861-864	the	abstract[44]	new[44]	_	_
9-6	865-873	clinical	abstract[44]	new[44]	_	_
9-7	874-884	conditions	abstract[44]	new[44]	_	_
9-8	885-891	appear	_	_	_	_
9-9	892-894	to	_	_	_	_
9-10	895-897	be	_	_	_	_
9-11	898-901	the	abstract[45]	new[45]	_	_
9-12	902-908	result	abstract[45]	new[45]	_	_
9-13	909-911	of	abstract[45]	new[45]	_	_
9-14	912-915	the	abstract[45]|abstract[46]	new[45]|new[46]	_	_
9-15	916-927	interaction	abstract[45]|abstract[46]	new[45]|new[46]	_	_
9-16	928-935	between	abstract[45]|abstract[46]	new[45]|new[46]	_	_
9-17	936-939	the	abstract[45]|abstract[46]|abstract[47]|abstract[48]	new[45]|new[46]|giv[47]|giv[48]	coref|coref|coref|coref	14-18[89_47]|19-18[135_48]|14-18[89_47]|19-18[135_48]
9-18	940-945	virus	abstract[45]|abstract[46]|abstract[47]|abstract[48]	new[45]|new[46]|giv[47]|giv[48]	_	_
9-19	946-949	and	abstract[45]|abstract[46]|abstract[48]	new[45]|new[46]|giv[48]	_	_
9-20	950-953	the	abstract[45]|abstract[46]|abstract[48]|abstract[50]	new[45]|new[46]|giv[48]|new[50]	_	_
9-21	954-958	host	abstract[45]|abstract[46]|abstract[48]|person|abstract[50]	new[45]|new[46]|giv[48]|new|new[50]	coref	20-38[146_0]
9-22	959-973	susceptibility	abstract[45]|abstract[46]|abstract[48]|abstract[50]	new[45]|new[46]|giv[48]|new[50]	_	_
9-23	974-975	,	_	_	_	_
9-24	976-983	leading	_	_	_	_
9-25	984-986	to	_	_	_	_
9-26	987-990	the	abstract[51]	new[51]	_	_
9-27	991-999	abnormal	abstract[51]	new[51]	_	_
9-28	1000-1011	functioning	abstract[51]	new[51]	_	_
9-29	1012-1014	of	abstract[51]	new[51]	_	_
9-30	1015-1032	immuno-modulatory	abstract[51]|abstract|abstract[53]	new[51]|new|new[53]	_	_
9-31	1033-1043	mechanisms	abstract[51]|abstract[53]	new[51]|new[53]	_	_
9-32	1044-1045	,	abstract[51]	new[51]	_	_
9-33	1046-1050	cell	abstract[51]|place|abstract[55]	new[51]|new|new[55]	coref|coref	16-8[112_55]|16-8[112_55]
9-34	1051-1064	proliferation	abstract[51]|abstract[55]	new[51]|new[55]	_	_
9-35	1065-1066	,	abstract[51]	new[51]	_	_
9-36	1067-1070	and	abstract[51]	new[51]	_	_
9-37	1071-1083	inflammation	abstract[51]|abstract	new[51]|new	_	_
9-38	1084-1085	.	_	_	_	_

#Text=HAM is a chronic progressive demyelinating disease that affects the spinal cord and the white matter of the brain , leading to a severe clinical syndrome due to the motor limitations that affect the lower limbs associated with the autonomic dysfunction .
10-1	1086-1089	HAM	abstract	giv	coref	10-3[59_0]
10-2	1090-1092	is	_	_	_	_
10-3	1093-1094	a	abstract[59]	giv[59]	coref	12-7[0_59]
10-4	1095-1102	chronic	abstract[59]	giv[59]	_	_
10-5	1103-1114	progressive	abstract[59]	giv[59]	_	_
10-6	1115-1128	demyelinating	abstract|abstract[59]	new|giv[59]	_	_
10-7	1129-1136	disease	abstract[59]	giv[59]	_	_
10-8	1137-1141	that	_	_	_	_
10-9	1142-1149	affects	_	_	_	_
10-10	1150-1153	the	object[60]	new[60]	_	_
10-11	1154-1160	spinal	object[60]	new[60]	_	_
10-12	1161-1165	cord	object[60]	new[60]	_	_
10-13	1166-1169	and	_	_	_	_
10-14	1170-1173	the	object[61]	new[61]	_	_
10-15	1174-1179	white	object[61]	new[61]	_	_
10-16	1180-1186	matter	object[61]	new[61]	_	_
10-17	1187-1189	of	object[61]	new[61]	_	_
10-18	1190-1193	the	object[61]|object[62]	new[61]|new[62]	_	_
10-19	1194-1199	brain	object[61]|object[62]	new[61]|new[62]	_	_
10-20	1200-1201	,	_	_	_	_
10-21	1202-1209	leading	_	_	_	_
10-22	1210-1212	to	_	_	_	_
10-23	1213-1214	a	abstract[63]	giv[63]	_	_
10-24	1215-1221	severe	abstract[63]	giv[63]	_	_
10-25	1222-1230	clinical	abstract[63]	giv[63]	_	_
10-26	1231-1239	syndrome	abstract[63]	giv[63]	_	_
10-27	1240-1243	due	abstract[63]	giv[63]	_	_
10-28	1244-1246	to	_	_	_	_
10-29	1247-1250	the	abstract[65]	new[65]	_	_
10-30	1251-1256	motor	object|abstract[65]	new|new[65]	_	_
10-31	1257-1268	limitations	abstract[65]	new[65]	_	_
10-32	1269-1273	that	_	_	_	_
10-33	1274-1280	affect	_	_	_	_
10-34	1281-1284	the	object[66]	new[66]	coref	12-18[77_66]
10-35	1285-1290	lower	object[66]	new[66]	_	_
10-36	1291-1296	limbs	object[66]	new[66]	_	_
10-37	1297-1307	associated	_	_	_	_
10-38	1308-1312	with	_	_	_	_
10-39	1313-1316	the	abstract[67]	new[67]	_	_
10-40	1317-1326	autonomic	abstract[67]	new[67]	_	_
10-41	1327-1338	dysfunction	abstract[67]	new[67]	_	_
10-42	1339-1340	.	_	_	_	_

#Text=The clinical picture begins and evolves insidiously , being difficult to establish when the first symptoms appeared .
11-1	1341-1344	The	abstract[68]	new[68]	_	_
11-2	1345-1353	clinical	abstract[68]	new[68]	_	_
11-3	1354-1361	picture	abstract[68]	new[68]	_	_
11-4	1362-1368	begins	_	_	_	_
11-5	1369-1372	and	_	_	_	_
11-6	1373-1380	evolves	_	_	_	_
11-7	1381-1392	insidiously	_	_	_	_
11-8	1393-1394	,	_	_	_	_
11-9	1395-1400	being	_	_	_	_
11-10	1401-1410	difficult	_	_	_	_
11-11	1411-1413	to	_	_	_	_
11-12	1414-1423	establish	_	_	_	_
11-13	1424-1428	when	_	_	_	_
11-14	1429-1432	the	abstract[69]	new[69]	coref	12-5[71_69]
11-15	1433-1438	first	abstract[69]	new[69]	_	_
11-16	1439-1447	symptoms	abstract[69]	new[69]	_	_
11-17	1448-1456	appeared	_	_	_	_
11-18	1457-1458	.	_	_	_	_

#Text=The main signs and symptoms of HAM may include gait disturbance , weakness , and stiffness of the lower limbs .
12-1	1459-1462	The	abstract[70]	new[70]	_	_
12-2	1463-1467	main	abstract[70]	new[70]	_	_
12-3	1468-1473	signs	abstract[70]	new[70]	_	_
12-4	1474-1477	and	_	_	_	_
12-5	1478-1486	symptoms	abstract[71]	giv[71]	coref	20-4[139_71]
12-6	1487-1489	of	abstract[71]	giv[71]	_	_
12-7	1490-1493	HAM	abstract[71]|abstract	giv[71]|giv	coref	13-5[79_0]
12-8	1494-1497	may	_	_	_	_
12-9	1498-1505	include	_	_	_	_
12-10	1506-1510	gait	abstract|abstract[74]	new|new[74]	_	_
12-11	1511-1522	disturbance	abstract[74]	new[74]	_	_
12-12	1523-1524	,	_	_	_	_
12-13	1525-1533	weakness	abstract	new	_	_
12-14	1534-1535	,	_	_	_	_
12-15	1536-1539	and	_	_	_	_
12-16	1540-1549	stiffness	abstract[76]	new[76]	_	_
12-17	1550-1552	of	abstract[76]	new[76]	_	_
12-18	1553-1556	the	abstract[76]|object[77]	new[76]|giv[77]	_	_
12-19	1557-1562	lower	abstract[76]|object[77]	new[76]|giv[77]	_	_
12-20	1563-1568	limbs	abstract[76]|object[77]	new[76]|giv[77]	_	_
12-21	1569-1570	.	_	_	_	_

#Text=The first manifestations of the disease occur in the fourth decade of life and there is a 2:1 woman/man ratio .
13-1	1571-1574	The	event[78]	new[78]	_	_
13-2	1575-1580	first	event[78]	new[78]	_	_
13-3	1581-1595	manifestations	event[78]	new[78]	_	_
13-4	1596-1598	of	event[78]	new[78]	_	_
13-5	1599-1602	the	event[78]|abstract[79]	new[78]|giv[79]	coref	15-5[0_79]
13-6	1603-1610	disease	event[78]|abstract[79]	new[78]|giv[79]	_	_
13-7	1611-1616	occur	_	_	_	_
13-8	1617-1619	in	_	_	_	_
13-9	1620-1623	the	time[80]	new[80]	_	_
13-10	1624-1630	fourth	time[80]	new[80]	_	_
13-11	1631-1637	decade	time[80]	new[80]	_	_
13-12	1638-1640	of	time[80]	new[80]	_	_
13-13	1641-1645	life	time[80]|time	new[80]|new	coref	14-1[85_0]
13-14	1646-1649	and	_	_	_	_
13-15	1650-1655	there	_	_	_	_
13-16	1656-1658	is	_	_	_	_
13-17	1659-1660	a	abstract[83]	new[83]	_	_
13-18	1661-1664	2:1	abstract[83]	new[83]	_	_
13-19	1665-1674	woman/man	person|abstract[83]	new|new[83]	_	_
13-20	1675-1680	ratio	abstract[83]	new[83]	_	_
13-21	1681-1682	.	_	_	_	_

#Text=The incubation period differs from patient to patient and seems to be shorter in the cases where the virus was acquired through blood transfusion .
14-1	1683-1686	The	time[85]	giv[85]	_	_
14-2	1687-1697	incubation	abstract|time[85]	new|giv[85]	_	_
14-3	1698-1704	period	time[85]	giv[85]	_	_
14-4	1705-1712	differs	_	_	_	_
14-5	1713-1717	from	_	_	_	_
14-6	1718-1725	patient	person	new	_	_
14-7	1726-1728	to	_	_	_	_
14-8	1729-1736	patient	person	new	_	_
14-9	1737-1740	and	_	_	_	_
14-10	1741-1746	seems	_	_	_	_
14-11	1747-1749	to	_	_	_	_
14-12	1750-1752	be	_	_	_	_
14-13	1753-1760	shorter	_	_	_	_
14-14	1761-1763	in	_	_	_	_
14-15	1764-1767	the	abstract[88]	new[88]	_	_
14-16	1768-1773	cases	abstract[88]	new[88]	_	_
14-17	1774-1779	where	_	_	_	_
14-18	1780-1783	the	abstract[89]	giv[89]	coref	15-48[106_89]
14-19	1784-1789	virus	abstract[89]	giv[89]	_	_
14-20	1790-1793	was	_	_	_	_
14-21	1794-1802	acquired	_	_	_	_
14-22	1803-1810	through	_	_	_	_
14-23	1811-1816	blood	substance|object[91]	new|new[91]	coref|coref	15-52[107_0]|15-52[107_0]
14-24	1817-1828	transfusion	object[91]	new[91]	_	_
14-25	1829-1830	.	_	_	_	_

#Text=Two important aspects of HAM development have been reported , including the efficiency of the cellular immune response and the rate of spontaneous expression of the viral antigen , due to the numerous immunological alterations , mediated mainly by the expression of Tax ( regulatory protein of the virus ) in the peripheral blood and in the cerebrospinal fluid of patients with HAM .
15-1	1831-1834	Two	abstract[92]	new[92]	_	_
15-2	1835-1844	important	abstract[92]	new[92]	_	_
15-3	1845-1852	aspects	abstract[92]	new[92]	_	_
15-4	1853-1855	of	abstract[92]	new[92]	_	_
15-5	1856-1859	HAM	abstract[92]|substance|event[94]	new[92]|giv|new[94]	coref|coref	15-63|15-63
15-6	1860-1871	development	abstract[92]|event[94]	new[92]|new[94]	_	_
15-7	1872-1876	have	_	_	_	_
15-8	1877-1881	been	_	_	_	_
15-9	1882-1890	reported	_	_	_	_
15-10	1891-1892	,	_	_	_	_
15-11	1893-1902	including	_	_	_	_
15-12	1903-1906	the	abstract[95]	new[95]	_	_
15-13	1907-1917	efficiency	abstract[95]	new[95]	_	_
15-14	1918-1920	of	abstract[95]	new[95]	_	_
15-15	1921-1924	the	abstract[95]|abstract[97]|abstract[98]	new[95]|new[97]|new[98]	coref|coref|coref|coref	18-14[126_97]|21-31[158_98]|18-14[126_97]|21-31[158_98]
15-16	1925-1933	cellular	abstract[95]|abstract[97]|abstract[98]	new[95]|new[97]|new[98]	_	_
15-17	1934-1940	immune	abstract[95]|abstract|abstract[97]|abstract[98]	new[95]|new|new[97]|new[98]	coref	17-11
15-18	1941-1949	response	abstract[95]|abstract[97]|abstract[98]	new[95]|new[97]|new[98]	_	_
15-19	1950-1953	and	abstract[95]|abstract[98]	new[95]|new[98]	_	_
15-20	1954-1957	the	abstract[95]|abstract[98]|abstract[99]	new[95]|new[98]|new[99]	_	_
15-21	1958-1962	rate	abstract[95]|abstract[98]|abstract[99]	new[95]|new[98]|new[99]	_	_
15-22	1963-1965	of	abstract[95]|abstract[98]|abstract[99]	new[95]|new[98]|new[99]	_	_
15-23	1966-1977	spontaneous	abstract[95]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[98]|new[99]|new[100]	_	_
15-24	1978-1988	expression	abstract[95]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[98]|new[99]|new[100]	_	_
15-25	1989-1991	of	abstract[95]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[98]|new[99]|new[100]	_	_
15-26	1992-1995	the	abstract[95]|abstract[98]|abstract[99]|abstract[100]|abstract[101]	new[95]|new[98]|new[99]|new[100]|new[101]	_	_
15-27	1996-2001	viral	abstract[95]|abstract[98]|abstract[99]|abstract[100]|abstract[101]	new[95]|new[98]|new[99]|new[100]|new[101]	_	_
15-28	2002-2009	antigen	abstract[95]|abstract[98]|abstract[99]|abstract[100]|abstract[101]	new[95]|new[98]|new[99]|new[100]|new[101]	_	_
15-29	2010-2011	,	_	_	_	_
15-30	2012-2015	due	_	_	_	_
15-31	2016-2018	to	_	_	_	_
15-32	2019-2022	the	abstract[102]	new[102]	_	_
15-33	2023-2031	numerous	abstract[102]	new[102]	_	_
15-34	2032-2045	immunological	abstract[102]	new[102]	_	_
15-35	2046-2057	alterations	abstract[102]	new[102]	_	_
15-36	2058-2059	,	_	_	_	_
15-37	2060-2068	mediated	_	_	_	_
15-38	2069-2075	mainly	_	_	_	_
15-39	2076-2078	by	_	_	_	_
15-40	2079-2082	the	abstract[103]	new[103]	_	_
15-41	2083-2093	expression	abstract[103]	new[103]	_	_
15-42	2094-2096	of	abstract[103]	new[103]	_	_
15-43	2097-2100	Tax	abstract[103]|abstract	new[103]|new	appos	15-45[105_0]
15-44	2101-2102	(	_	_	_	_
15-45	2103-2113	regulatory	abstract[105]	giv[105]	_	_
15-46	2114-2121	protein	abstract[105]	giv[105]	_	_
15-47	2122-2124	of	abstract[105]	giv[105]	_	_
15-48	2125-2128	the	abstract[105]|abstract[106]	giv[105]|giv[106]	_	_
15-49	2129-2134	virus	abstract[105]|abstract[106]	giv[105]|giv[106]	_	_
15-50	2135-2136	)	_	_	_	_
15-51	2137-2139	in	_	_	_	_
15-52	2140-2143	the	substance[107]	giv[107]	_	_
15-53	2144-2154	peripheral	substance[107]	giv[107]	_	_
15-54	2155-2160	blood	substance[107]	giv[107]	_	_
15-55	2161-2164	and	_	_	_	_
15-56	2165-2167	in	_	_	_	_
15-57	2168-2171	the	substance[108]	new[108]	_	_
15-58	2172-2185	cerebrospinal	substance[108]	new[108]	_	_
15-59	2186-2191	fluid	substance[108]	new[108]	_	_
15-60	2192-2194	of	substance[108]	new[108]	_	_
15-61	2195-2203	patients	substance[108]|person[109]	new[108]|giv[109]	_	_
15-62	2204-2208	with	substance[108]|person[109]	new[108]|giv[109]	_	_
15-63	2209-2212	HAM	substance[108]|person[109]|abstract	new[108]|giv[109]|giv	coref	19-24
15-64	2213-2214	.	_	_	_	_

#Text=In order to control HTLV-1 replication and the proliferation of infected cells , CD8+
16-1	2215-2217	In	_	_	_	_
16-2	2218-2223	order	_	_	_	_
16-3	2224-2226	to	_	_	_	_
16-4	2227-2234	control	_	_	_	_
16-5	2235-2241	HTLV-1	abstract[111]	new[111]	_	_
16-6	2242-2253	replication	abstract[111]	new[111]	_	_
16-7	2254-2257	and	_	_	_	_
16-8	2258-2261	the	abstract[112]	giv[112]	_	_
16-9	2262-2275	proliferation	abstract[112]	giv[112]	_	_
16-10	2276-2278	of	abstract[112]	giv[112]	_	_
16-11	2279-2287	infected	abstract[112]|object[113]	giv[112]|new[113]	appos	16-14[0_113]
16-12	2288-2293	cells	abstract[112]|object[113]	giv[112]|new[113]	_	_
16-13	2294-2295	,	_	_	_	_
16-14	2296-2300	CD8+	object	giv	coref	18-4[124_0]

#Text=T lymphocytes mediate the main defense strategy of the host immune system .
17-1	2301-2302	T	person|place[116]	new|new[116]	coref|coref	18-5|18-5
17-2	2303-2314	lymphocytes	place[116]	new[116]	_	_
17-3	2315-2322	mediate	_	_	_	_
17-4	2323-2326	the	abstract[118]	new[118]	_	_
17-5	2327-2331	main	abstract[118]	new[118]	_	_
17-6	2332-2339	defense	abstract|abstract[118]	new|new[118]	_	_
17-7	2340-2348	strategy	abstract[118]	new[118]	_	_
17-8	2349-2351	of	abstract[118]	new[118]	_	_
17-9	2352-2355	the	abstract[118]|abstract[120]	new[118]|new[120]	coref	18-20[128_120]
17-10	2356-2360	host	abstract[118]|abstract[120]	new[118]|new[120]	_	_
17-11	2361-2367	immune	abstract[118]|abstract|abstract[120]	new[118]|giv|new[120]	coref	18-22
17-12	2368-2374	system	abstract[118]|abstract[120]	new[118]|new[120]	_	_
17-13	2375-2376	.	_	_	_	_

#Text=HTLV-1 infects mainly CD4+ T cells , which are the central regulators of the acquired immune response , deregulating the host immune system .
18-1	2377-2383	HTLV-1	abstract	giv	coref	19-6
18-2	2384-2391	infects	_	_	_	_
18-3	2392-2398	mainly	_	_	_	_
18-4	2399-2403	CD4+	substance|object[124]	new|giv[124]	coref|coref|coref|coref	19-8|19-8[133_124]|19-8|19-8[133_124]
18-5	2404-2405	T	person|object[124]	giv|giv[124]	coref	19-9
18-6	2406-2411	cells	object[124]	giv[124]	_	_
18-7	2412-2413	,	_	_	_	_
18-8	2414-2419	which	_	_	_	_
18-9	2420-2423	are	_	_	_	_
18-10	2424-2427	the	substance[125]	new[125]	_	_
18-11	2428-2435	central	substance[125]	new[125]	_	_
18-12	2436-2446	regulators	substance[125]	new[125]	_	_
18-13	2447-2449	of	substance[125]	new[125]	_	_
18-14	2450-2453	the	substance[125]|abstract[126]	new[125]|giv[126]	coref	21-31[157_126]
18-15	2454-2462	acquired	substance[125]|abstract[126]	new[125]|giv[126]	_	_
18-16	2463-2469	immune	substance[125]|abstract[126]	new[125]|giv[126]	_	_
18-17	2470-2478	response	substance[125]|abstract[126]	new[125]|giv[126]	_	_
18-18	2479-2480	,	_	_	_	_
18-19	2481-2493	deregulating	_	_	_	_
18-20	2494-2497	the	abstract[128]	giv[128]	coref	21-54[167_128]
18-21	2498-2502	host	abstract[128]	giv[128]	_	_
18-22	2503-2509	immune	abstract|abstract[128]	giv|giv[128]	_	_
18-23	2510-2516	system	abstract[128]	giv[128]	_	_
18-24	2517-2518	.	_	_	_	_

#Text=To establish persistent infection , HTLV-1 deregulates CD4+ T cells , sometimes leading to ATLL or to chronic inflammatory diseases , such as HAM and uveitis .
19-1	2519-2521	To	_	_	_	_
19-2	2522-2531	establish	_	_	_	_
19-3	2532-2542	persistent	abstract[129]	new[129]	coref	20-48[150_129]
19-4	2543-2552	infection	abstract[129]	new[129]	_	_
19-5	2553-2554	,	_	_	_	_
19-6	2555-2561	HTLV-1	place	giv	coref	20-48
19-7	2562-2573	deregulates	_	_	_	_
19-8	2574-2578	CD4+	substance|object[133]	giv|giv[133]	_	_
19-9	2579-2580	T	person|object[133]	giv|giv[133]	_	_
19-10	2581-2586	cells	object[133]	giv[133]	_	_
19-11	2587-2588	,	_	_	_	_
19-12	2589-2598	sometimes	_	_	_	_
19-13	2599-2606	leading	_	_	_	_
19-14	2607-2609	to	_	_	_	_
19-15	2610-2614	ATLL	abstract[134]	giv[134]	_	_
19-16	2615-2617	or	abstract[134]	giv[134]	_	_
19-17	2618-2620	to	abstract[134]	giv[134]	_	_
19-18	2621-2628	chronic	abstract[134]|abstract[135]	giv[134]|giv[135]	coref	20-20[143_135]
19-19	2629-2641	inflammatory	abstract[134]|abstract[135]	giv[134]|giv[135]	_	_
19-20	2642-2650	diseases	abstract[134]|abstract[135]	giv[134]|giv[135]	_	_
19-21	2651-2652	,	abstract[134]	giv[134]	_	_
19-22	2653-2657	such	abstract[134]	giv[134]	_	_
19-23	2658-2660	as	abstract[134]	giv[134]	_	_
19-24	2661-2664	HAM	abstract[134]|substance	giv[134]|giv	_	_
19-25	2665-2668	and	abstract[134]	giv[134]	_	_
19-26	2669-2676	uveitis	abstract[134]|abstract	giv[134]|new	_	_
19-27	2677-2678	.	_	_	_	_

#Text=The absence of symptoms in most of the infected people raises the question of the multiple etiological roles of the virus-associated diseases and some of the interesting questions still unanswered includes : does the immunogenic characteristics of the host contribute to the upsurge of symptoms associated with HTLV-1 infection ?
20-1	2679-2682	The	abstract[138]	new[138]	_	_
20-2	2683-2690	absence	abstract[138]	new[138]	_	_
20-3	2691-2693	of	abstract[138]	new[138]	_	_
20-4	2694-2702	symptoms	abstract[138]|abstract[139]	new[138]|giv[139]	coref	20-45[0_139]
20-5	2703-2705	in	abstract[138]|abstract[139]	new[138]|giv[139]	_	_
20-6	2706-2710	most	abstract[138]|abstract[139]|person[140]	new[138]|giv[139]|giv[140]	_	_
20-7	2711-2713	of	person[140]	giv[140]	_	_
20-8	2714-2717	the	person[140]	giv[140]	_	_
20-9	2718-2726	infected	person[140]	giv[140]	_	_
20-10	2727-2733	people	person[140]	giv[140]	_	_
20-11	2734-2740	raises	_	_	_	_
20-12	2741-2744	the	abstract[141]	new[141]	_	_
20-13	2745-2753	question	abstract[141]	new[141]	_	_
20-14	2754-2756	of	abstract[141]	new[141]	_	_
20-15	2757-2760	the	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-16	2761-2769	multiple	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-17	2770-2781	etiological	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-18	2782-2787	roles	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-19	2788-2790	of	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-20	2791-2794	the	abstract[141]|abstract[142]|abstract[143]	new[141]|new[142]|giv[143]	_	_
20-21	2795-2811	virus-associated	abstract[141]|abstract[142]|abstract[143]	new[141]|new[142]|giv[143]	_	_
20-22	2812-2820	diseases	abstract[141]|abstract[142]|abstract[143]	new[141]|new[142]|giv[143]	_	_
20-23	2821-2824	and	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-24	2825-2829	some	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-25	2830-2832	of	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-26	2833-2836	the	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
20-27	2837-2848	interesting	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
20-28	2849-2858	questions	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
20-29	2859-2864	still	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
20-30	2865-2875	unanswered	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
20-31	2876-2884	includes	_	_	_	_
20-32	2885-2886	:	_	_	_	_
20-33	2887-2891	does	_	_	_	_
20-34	2892-2895	the	abstract[145]	new[145]	_	_
20-35	2896-2907	immunogenic	abstract[145]	new[145]	_	_
20-36	2908-2923	characteristics	abstract[145]	new[145]	_	_
20-37	2924-2926	of	abstract[145]	new[145]	_	_
20-38	2927-2930	the	abstract[145]|person[146]	new[145]|giv[146]	coref	21-27[156_146]
20-39	2931-2935	host	abstract[145]|person[146]	new[145]|giv[146]	_	_
20-40	2936-2946	contribute	_	_	_	_
20-41	2947-2949	to	_	_	_	_
20-42	2950-2953	the	abstract[147]	new[147]	_	_
20-43	2954-2961	upsurge	abstract[147]	new[147]	_	_
20-44	2962-2964	of	abstract[147]	new[147]	_	_
20-45	2965-2973	symptoms	abstract[147]|abstract	new[147]|giv	_	_
20-46	2974-2984	associated	_	_	_	_
20-47	2985-2989	with	_	_	_	_
20-48	2990-2996	HTLV-1	object|abstract[150]	giv|giv[150]	coref|coref|coref|coref	21-35|21-35[160_150]|21-35|21-35[160_150]
20-49	2997-3006	infection	abstract[150]	giv[150]	_	_
20-50	3007-3008	?	_	_	_	_

#Text=The present manuscript presents the most relevant published results from several laboratories , including ours over the years regarding the associations between the genetic variations of the host related to the immune response and HTLV-1 infection , particularly those showing the close relationship between HTLV-1 infection and single nucleotide polymorphisms in genes of the immune system .
21-1	3009-3012	The	object[151]	new[151]	_	_
21-2	3013-3020	present	object[151]	new[151]	_	_
21-3	3021-3031	manuscript	object[151]	new[151]	_	_
21-4	3032-3040	presents	_	_	_	_
21-5	3041-3044	the	abstract[152]	new[152]	_	_
21-6	3045-3049	most	abstract[152]	new[152]	_	_
21-7	3050-3058	relevant	abstract[152]	new[152]	_	_
21-8	3059-3068	published	abstract[152]	new[152]	_	_
21-9	3069-3076	results	abstract[152]	new[152]	_	_
21-10	3077-3081	from	abstract[152]	new[152]	_	_
21-11	3082-3089	several	abstract[152]|place[153]	new[152]|new[153]	_	_
21-12	3090-3102	laboratories	abstract[152]|place[153]	new[152]|new[153]	_	_
21-13	3103-3104	,	_	_	_	_
21-14	3105-3114	including	_	_	_	_
21-15	3115-3119	ours	_	_	_	_
21-16	3120-3124	over	_	_	_	_
21-17	3125-3128	the	_	_	_	_
21-18	3129-3134	years	_	_	_	_
21-19	3135-3144	regarding	_	_	_	_
21-20	3145-3148	the	abstract[154]	new[154]	_	_
21-21	3149-3161	associations	abstract[154]	new[154]	_	_
21-22	3162-3169	between	abstract[154]	new[154]	_	_
21-23	3170-3173	the	abstract[154]|abstract[155]	new[154]|new[155]	_	_
21-24	3174-3181	genetic	abstract[154]|abstract[155]	new[154]|new[155]	_	_
21-25	3182-3192	variations	abstract[154]|abstract[155]	new[154]|new[155]	_	_
21-26	3193-3195	of	abstract[154]|abstract[155]	new[154]|new[155]	_	_
21-27	3196-3199	the	abstract[154]|abstract[155]|person[156]	new[154]|new[155]|giv[156]	_	_
21-28	3200-3204	host	abstract[154]|abstract[155]|person[156]	new[154]|new[155]|giv[156]	_	_
21-29	3205-3212	related	_	_	_	_
21-30	3213-3215	to	_	_	_	_
21-31	3216-3219	the	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
21-32	3220-3226	immune	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
21-33	3227-3235	response	abstract[157]|abstract[158]	giv[157]|giv[158]	_	_
21-34	3236-3239	and	abstract[158]	giv[158]	_	_
21-35	3240-3246	HTLV-1	abstract[158]|object|abstract[160]	giv[158]|giv|giv[160]	coref|coref|coref|coref	21-45|21-45[163_160]|21-45|21-45[163_160]
21-36	3247-3256	infection	abstract[158]|abstract[160]	giv[158]|giv[160]	_	_
21-37	3257-3258	,	_	_	_	_
21-38	3259-3271	particularly	_	_	_	_
21-39	3272-3277	those	_	_	_	_
21-40	3278-3285	showing	_	_	_	_
21-41	3286-3289	the	abstract[161]	new[161]	_	_
21-42	3290-3295	close	abstract[161]	new[161]	_	_
21-43	3296-3308	relationship	abstract[161]	new[161]	_	_
21-44	3309-3316	between	abstract[161]	new[161]	_	_
21-45	3317-3323	HTLV-1	abstract[161]|object|abstract[163]	new[161]|giv|giv[163]	_	_
21-46	3324-3333	infection	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
21-47	3334-3337	and	abstract[161]	new[161]	_	_
21-48	3338-3344	single	abstract[161]|abstract[165]	new[161]|new[165]	_	_
21-49	3345-3355	nucleotide	abstract[161]|place|abstract[165]	new[161]|new|new[165]	_	_
21-50	3356-3369	polymorphisms	abstract[161]|abstract[165]	new[161]|new[165]	_	_
21-51	3370-3372	in	abstract[161]|abstract[165]	new[161]|new[165]	_	_
21-52	3373-3378	genes	abstract[161]|abstract[165]|abstract[166]	new[161]|new[165]|new[166]	_	_
21-53	3379-3381	of	abstract[161]|abstract[165]|abstract[166]	new[161]|new[165]|new[166]	_	_
21-54	3382-3385	the	abstract[161]|abstract[165]|abstract[166]|abstract[167]	new[161]|new[165]|new[166]|giv[167]	_	_
21-55	3386-3392	immune	abstract[161]|abstract[165]|abstract[166]|abstract[167]	new[161]|new[165]|new[166]|giv[167]	_	_
21-56	3393-3399	system	abstract[161]|abstract[165]|abstract[166]|abstract[167]	new[161]|new[165]|new[166]|giv[167]	_	_
21-57	3400-3401	.	_	_	_	_
